XERS

AI MemoPost-earnings T+3

Xeris Biopharma

As of 2026-08-08/Post-earnings T+3/Confidence medium

Open ticker Back to Memos

Data freshness

AI Memo

As of 2026-08-08 • Model: RankAlpha Sentiment Codex

Decision Panel

Action, confidence, horizon, and decision blockers at a glance.

Action

—

Confidence

medium

Horizon

—

Key catalyst

Q2 2026 results strengthen the commercial execution read-through • 2026-08-06

Expected move: +20%

Biggest risk

The thesis remains dependent on Recorlev and commercial execution. Gvoke revenue declined 4% year over year, SG&A rose 37%, R&D rose 32%, and the company still reported a net loss, although the loss was largely driven by a one-time non-cash convertible-notes charge. No reliable post-print analyst estimate or target revisions were available.

Invalidation

Break below $6 or thesis failure.

What would change my mind?

The Q2 print supports a constructive operating thesis: Recorlev is scaling rapidly, gross margin and adjusted EBITDA improved, and management raised the low end of full-year revenue guidance. XP-8121 Phase 3 execution could provide an additional value inflection.

Research note

Recommendation

—

Confidence

medium

As of

2026-08-08

Base target

$10

p=55%

Bull target

$13

p=25%

Bear target

p=20%

Key bullets

Fast scan of bull, bear, and watch items

BullKey bullets

Post-print momentum depends on guidance credibility
XP-8121 Phase 3 initiation remains the main pipeline inflection
Keveyis patent protection supports long-duration commercial value

BearKey bullets

Gvoke revenue declined 4% year over year while SG&A and R&D increased materially.
Low analyst coverage leaves post-earnings estimate revisions and target changes unavailable.
Recent officer open-market sales are a secondary sentiment risk, not evidence of operating weakness [#SEC-FORM4-2026-08-04].

WatchKey bullets

Q2 2026 results strengthen the commercial execution read-through

Summary

High-level snapshot

Recommendation

Model confidence

medium

Timeframe

Asset

Equity

Trigger

Post-earnings T+3

Base case: $10 (p=55%)

Bull/Bear spread: +58% / -24%

Vs latest close: Bull +58% · Base +20% · Bear -24%

Scenario probabilities

Bull Target: $13 (p=25%)Base Target: $10 (p=55%)Bear Target: $6 (p=20%)

Commentary

Official post-earnings news flow is moderately constructive because of strong Recorlev growth, improved adjusted EBITDA, and tighter guidance. The positive Aug. 7 price reaction supports initial acceptance, but no trusted analyst revision or target-change evidence was found. Social data and options data were unavailable, so this remains a cautious monitoring view rather than a high-conviction upgrade.

As of 2026-08-08 • Updated bi-weekly / post-earningsSource: Internal modelMethodology

Analyst Summary

Thesis highlights from the latest analysis

Bull Case

Bear Case

Drivers

Scannable catalysts and supporting factors

Post-print momentum depends on guidance credibility
XP-8121 Phase 3 initiation remains the main pipeline inflection
Keveyis patent protection supports long-duration commercial value

Scenarios

Bull Target (Scenario probability)

$13 / p=25% prob

Base Target (Scenario probability)

$10 / p=55% prob

Bear Target (Scenario probability)

$6 / p=20% prob

Price $8 as of 2026-08-07

Nearest Scenario: Base (∆ 20%)

Targets vs latest close: Bull +58% · Base +20% · Bear -24%

Sentiment & Exposure

News Sentiment (30d)

0.68

Social Sentiment (7d)

0.00

Events

Other notable items detected

EVENT2026-08-06
Q2 2026 results strengthen the commercial execution read-through
Xeris reported Q2 revenue of $92.1 million, net product revenue growth of 34%, Recorlev growth of 81%, 86% gross margin, and $19.3 million of adjusted EBITDA. Management also tightened full-year 2026 revenue guidance to $385-$390 million [#SEC-8K-2026-08-06] ([SEC earnings exhibit](https://www.sec.gov/Archives/edgar/data/1867096/000186709626000063/exh991q22026earningsrelease.htm)).
Prob 90.00% • Move 8.00% • Priced-in 75.00%

Short-term Catalysts

Next few weeks

Post-print momentum depends on guidance credibility
2026-08-08
The Aug. 7 price response was positive, with a live quote snapshot showing $7.93, up $0.56, or 7.6%, versus the prior close ([market quote](https://finance.yahoo.com/quote/XERS/)). Further upside requires sustained Recorlev demand and confirmation that the narrowed revenue guide is achievable.
Prob 65% • Move 6% • Priced-in 60%

Long-term Catalysts

Months to a year

XP-8121 Phase 3 initiation remains the main pipeline inflection
2026-12-31
XP-8121 is described as a Phase 3-ready lead program, with anticipated Phase 3 initiation later in 2026. Successful execution would broaden the value proposition beyond the marketed portfolio, while delay would weaken the pipeline narrative [#10-K-2026-03-02].
Prob 55% • Move 18% • Priced-in 35%
Keveyis patent protection supports long-duration commercial value
2039-12-31
Xeris disclosed a USPTO Notice of Allowance for a new Keveyis patent expected to extend protection through at least 2039 [#SEC-8K-2026-08-06]. This is supportive of long-term franchise durability but is unlikely to be a near-term earnings driver.
Prob 80% • Move 8% • Priced-in 60%

Risks

Gvoke revenue declined 4% year over year while SG&A and R&D increased materially.
Low analyst coverage leaves post-earnings estimate revisions and target changes unavailable.
Recent officer open-market sales are a secondary sentiment risk, not evidence of operating weakness [#SEC-FORM4-2026-08-04].
Recorlev concentration creates execution and demand risk if commercial expansion underperforms.
The Q2 net loss included an approximately $31 million non-cash charge tied to the 2028 Convertible Notes exchange agreements [#SEC-8K-2026-08-06].
XP-8121 Phase 3 initiation or development could be delayed [#10-K-2026-03-02].

Peers

Symbol	Summary
GLUE	Loose same-sector market-cap peer; development-stage biotech economics are not directly comparable with Xeris's commercial product portfolio.
ORIC	Loose same-sector market-cap peer with pipeline-heavy economics; useful mainly for risk-appetite context rather than operating benchmarking.
LBRX	Small-cap biopharma peer by sector and market capitalization, but no direct operating comparability was established in the packet.

Sources

Internal and external references used in this analysis

Model source: RankAlpha Sentiment Codex
Analysis date: 2026-08-08

AI Stock Memo: XERS - Xeris Biopharma - RankAlpha